NVE Corp. Q3 contract research and development revenue up over fourfold to USD 0.45 million

Reuters
01/22
NVE Corp. Q3 contract research and development revenue up over fourfold to USD 0.45 million

NVE Corporation reported financial results for the third quarter (Q3) ended December 31, 2025. Total revenue for Q3 rose 23 percent to USD 6.2 million, driven by a 16 percent increase in product sales and contract research and development revenue that was more than three times higher year over year. Net income for the quarter was USD 3.4 million, an increase of 11 percent, with diluted earnings per share at USD 0.70. For the first nine months (9M) of fiscal 2026, total revenue was USD 18.7 million, up 0.4 percent. Net income for the nine-month period was USD 10.3 million, with diluted earnings per share at USD 2.12. The company also announced a quarterly cash dividend of USD 1.00 per share, payable on February 27, 2026, to shareholders of record as of February 2, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NVE Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001376474-26-000058), on January 21, 2026, and is solely responsible for the information contained therein.

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10